title: Reproductive toxicity testing of vaccines.
abstract: Vaccines play a major role in the prevention of human birth defects by protecting the pregnant woman from teratogenic or otherwise harmful infections. Until now, it has not been common practice to perform preclinical developmental toxicity tests for new vaccines. Despite the excellent safety record of vaccines, increased attention is now being given to the feasibility of screening new vaccines for developmental hazards in animals before their use in humans. Contrary to previous assumptions, many vaccines are now given to potentially pregnant women. Any new components of the vaccine formulation (adjuvants, excipients, stabilisers, preservatives, etc.) could also be tested for influences on development, although based on past experience the risks are limited by the very low dosages used. The conferred immunity following vaccination lasts for several years. Therefore, the developing conceptus may theoretically be exposed to the induced antibodies and/or sensitised T-cells, even if the pregnant woman was last vaccinated during childhood (particularly if she encounters the antigen during pregnancy through exposure to infection). However, it should be kept in mind that viral or bacterial infections represent a higher risk for a pregnant woman than the potential adverse effects related to vaccination or the associated immune response. Non-clinical safety studies may be employed as an aid for hazard identification. In these studies interactions of the vaccine with the maternal immune system or with the developmental systems of the offspring are considered. Post-natal examinations are necessary to detect all possible manifestations of developmental toxicity, such as effects on the immune system. Species selection for the preclinical studies is based on immunogenicity to the vaccine and the relative timing and rate of transfer of maternal antibodies to the offspring. A single study design is proposed for the pre- and post-natal developmental assessments of vaccines in rodents and rabbits.
authors.affiliation: Aventis Pasteur, Campus Merieux, 1541 avenue Marcel Mérieux, 69280 Marcy l'Etoile, France. francois.verdier@aventis.com
authors.forename: François
authors.initials: F
authors.lastname: Verdier
authors.forename: Paul C
authors.initials: PC
authors.lastname: Barrow
authors.forename: Joëlle
authors.initials: J
authors.lastname: Burge
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000473:pathology*; D000328:Adult; D000818:Animals; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007136:Immunoglobulins / Q000276:immunology; D007883:Legislation, Medical; D022401:Meningococcal Vaccines / Q000009:adverse effects / Q000633:toxicity; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology; D011247:Pregnancy; D012098:Reproduction / Q000187:drug effects*; D013723:Teratogens / Q000633:toxicity*; D014612:Vaccines / Q000633:toxicity*
chemical_list: D007136:Immunoglobulins; D022401:Meningococcal Vaccines; D013723:Teratogens; D014612:Vaccines